logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

A Note To Our Followers

Dear Friends and Followers, We confirm our optimism towards the future biotech firms that we selected for investment, including the clinical stage small biotech companies, which also includes biotech stocks that you have never heard about from us.  We  inform...

Read More

December 23, 2022

0

Compugen: Good News During Bad Market Days

The market is sinking in a furious mood caused by the failure to figure out the pathway of criteria, which is currently controlling the stocks’ volatile performances. Today we are posting good news coming from a few biotech companies with...

Read More

February 23, 2021

0

The QIAGEN and Inovio Pharmaceuticals Partnership Extension  

QIAGEN and Inovio Pharmaceuticals Partnership QIAGEN ( QGEN ) and Inovio Pharmaceuticals ( INO ) announced an extension of their partnership. The extension comprises a new agreement for the development of liquid biopsy-based companion diagnostic products. These products are made...

Read More

February 25, 2021

0

Gilead Sciences: The FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies. See Also: BioNTech

FDA Lifts Partial Clinical Hold on Gilead Sciences Studies of Magrolimab On April 12, 2022, Gilead Sciences ( GILD ) announced that the U.S. FDA lifted the partial clinical hold placed on studies evaluating its investigational agent magrolimab in combination...

Read More

April 13, 2022

0

The Johnson & Johnson COVID-19 Vaccine: Helping to Increase the Pressure on the Virus

Johnson & Johnson Receives an EUA from the U.S. FDA We appreciate the U.S. Food and Drug Administration's emergency use authorization ( EUA ) for the third vaccine for the prevention of SARS-CoV-2 (the virus that causes COVID-19). Three vaccines...

Read More

March 1, 2021

0

Interesting News from PTC Therapeutics and Arcturus Therapeutics Holdings

Arcturus Therapeutics Holdings News Arcturus Therapeutics Holdings ( ARCT ) shared topline data from an ongoing Phase 1/2/3 trial evaluating ARCT-154, Arcturus’ self-amplifying mRNA vaccine candidate against COVID-19. The ongoing Phase 1/2/3 registrational study, sponsored by Arcturus’ collaborator  Vinbiocare Biotechnology...

Read More

April 20, 2022

0

The FDA Approved KemPharm Inc's AZSTARYS™ for ADHD

KemPharm Inc KemPharm Inc ( KMPH ) - a specialty pharmaceutical focused on the discovery and development of proprietary prodrugs, announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for AZSTARYS™ , a...

Read More

March 3, 2021

0

Why Investors Have Enthusiasm for CureVac N.V.

CureVac N.V. in the News CureVac N.V. ( CVAC ) announced that after more than 10 years as a member of the CureVac management board and three years as CEO, Dr. Franz Haas will step down as CEO, effective March...

Read More

January 10, 2023

0

Ionis and Royalty Pharma Enter into a Royalty Agreement for Up to $1.1B

Ionis Pharmaceuticals and Royalty Pharma Ionis Pharmaceuticals ( IONS ) and Royalty Pharma plc ( RPRX ) announced that Royalty Pharma has acquired an interest in Ionis' royalty in Biogen's SPINRAZA® (nusinersen) and Novartis' pelacarsen for up to $1.125 billion, including an...

Read More

January 13, 2023

0

Jazz Pharmaceuticals and Zymeworks Product Zanidatamab Advance the Treatment of HER2-expressing mGA

Jazz Pharmaceuticals and Zymeworks Inc Announce Results of Zanidatamab Jazz Pharmaceuticals ( JAZZ ) and  Zymeworks Inc. ( ZYME ) announced first overall survival ( OS ) data from a Phase 2 trial examining zanidatamab. Zanidatamab.is a HER2-targeted bispecific antibody used...

Read More

January 20, 2023

0

  • Previous
  • 1
  • 2
  • ...
  • 38
  • 39
  • 40
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy